These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 22783045)

  • 41. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
    Abuodeh Y; Naghavi AO; Ahmed KA; Venkat PS; Kim Y; Kis B; Choi J; Biebel B; Sweeney J; Anaya DA; Kim R; Malafa M; Frakes JM; Hoffe SE; El-Haddad G
    World J Gastroenterol; 2016 Dec; 22(47):10406-10414. PubMed ID: 28058021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
    Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
    Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
    Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas.
    Noda Y; Kanematsu M; Goshima S; Suzui N; Hirose Y; Matsunaga K; Nishibori H; Kondo H; Watanabe H; Kawada H; Kawai N; Tanahashi Y; Bae KT
    Eur Radiol; 2015 Oct; 25(10):3009-16. PubMed ID: 25854217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
    Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer.
    Chung HH; Kang SY; Ha S; Kim JW; Park NH; Song YS; Cheon GJ
    J Gynecol Oncol; 2016 Mar; 27(2):e15. PubMed ID: 26768781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluorine-18-fluorodeoxyglucose uptake of bone marrow on PET/CT can predict prognosis in patients with colorectal cancer after curative surgical resection.
    Lee JW; Baek MJ; Ahn TS; Lee SM
    Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):187-194. PubMed ID: 29120905
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?
    Cheung TT; Chan SC; Ho CL; Chok KS; Chan AC; Sharr WW; Ng KK; Poon RT; Lo CM; Fan ST
    Liver Transpl; 2011 Oct; 17(10):1218-25. PubMed ID: 21688383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
    Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
    Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
    Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
    J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology.
    Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S
    Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
    Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
    Pant V; Sen IB; Soin AS
    Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
    Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Kang YK; Choi JY; Paeng JC; Kim YI; Kwon HW; Cheon GJ; Suh KS; Kwon CHD; Lee DS; Kang KW
    Eur Radiol; 2019 Nov; 29(11):6009-6017. PubMed ID: 31115626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using 18F-Fluoroethylcholine PET/CT.
    Hartenbach M; Weber S; Albert NL; Hartenbach S; Hirtl A; Zacherl MJ; Paprottka PM; Tiling R; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1661-6. PubMed ID: 26405170
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.
    Refaat R; Basha MAA; Hassan MS; Hussein RS; El Sammak AA; El Sammak DAEA; Radwan MHS; Awad NM; Saad El-Din SA; Elkholy E; Ibrahim DRD; Saleh SA; Montasser IF; Said H
    Eur Radiol; 2018 Dec; 28(12):5356-5367. PubMed ID: 29948070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.